Kalaris Therapeutics, Inc. (KLRS): Total Liabilities
$42.92M
As of 2025-12-31
$41.87M
As of 2026-06-30
-6.5%
3-year compound annual growth
+19.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.92M | -24.4% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $56.78M | +26.1% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $45.02M | -14.4% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $52.56M | -14.3% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $61.33M | +245.4% | 2023-02-15, Balance as of period end |
| 2020-12-31 | $17.76M | -0.2% | 2022-02-10, Balance as of period end |
| 2019-12-31 | $17.80M | n/a | 2021-02-12, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $42.92M | -24.4% |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $52.40M | -8.3% |
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $73.27M | +80.7% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $113.26M | -40.6% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $12.41M | -36.4% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $20.97M | -8.6% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $4.96M | +46.5% |
Compare KLRS, ABOS, CADL, HUMA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗